TABLE 2.
Distribution and extent of mucosal infections by treatmenta
| Treatment | Mucosal scoreb (mean ± SD)
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Stomach | Duodenum | SI-1c | SI-2c | SI-3c | Terminal ileum | Cecum | Colon | Total | |
| Paromomycin | |||||||||
| 2,000 mg | 1.0 ± 0.0 | 0.0 ± 0.0 | 0.5 ± 0.5 | 0.8 ± 0.4 | 0.8 ± 0.4 | 2.1 ± 0.9 | 3.0 ± 0.8 | 2.1 ± 0.7 | 10.3 ± 0.8 |
| 1,000 mg | 0.8 ± 0.4 | 0.4 ± 0.5 | 1.4 ± 1.5 | 3.2 ± 1.6 | 3.2 ± 1.7 | 1.8 ± 0.8 | 3.8 ± 0.4 | 2.2 ± 1.0 | 16.6 ± 5.4 |
| 500 mg | 1.5 ± 0.5 | 0.4 ± 0.5 | 0.6 ± 0.5 | 1.5 ± 0.7 | 4.8 ± 0.3 | 3.5 ± 0.7 | 4.4 ± 0.5 | 0.7 ± 0.7 | 18.4 ± 1.7 |
| None (placebo) | 1.5 ± 1.0 | 3.7 ± 1.5 | 4.7 ± 0.5 | 4.5 ± 1.0 | 4.2 ± 0.9 | 4.5 ± 0.5 | 2.7 ± 0.5 | 1.7 ± 0.5 | 28.0 ± 1.5 |
a
Measured at necropsy, 15 days after challenge with 5,000 oocytes per mouse, and at the end of a 10-day treatment period.
b
0, no infection; 1, difficult-to-find parasite forms; 2, sparse but easy-to-find parasite forms; 3, abundant presence, but focally distributed; 4, extensive presence, covering most mucosal surfaces; 5, extensive presence, covering entire mucosal surfaces.
c
Equally spaced sites in small intestine.